Utama › Limfoma Sel-B › Texas › Houston
Kajian klinikal Limfoma Sel-B di Houston, TX
16 kajian untuk Limfoma Sel-B sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mengambil pesertaFasa 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Mengambil pesertaFasa 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Mengambil pesertaFasa 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Mengambil pesertaFasa 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Mengambil pesertaFasa 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Mengambil pesertaFasa 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Mengambil pesertaFasa 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Mengambil pesertaFasa 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Mengambil pesertaFasa 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Kajian Limfoma Sel-B di bandar lain
- New York City, NY19 kajian
- Chicago, IL12 kajian
- Nashville, TN11 kajian
- Philadelphia, PA11 kajian
- Rochester, MN10 kajian
- Baldwin Park, CA9 kajian
- Milwaukee, WI9 kajian
- Cleveland, OH9 kajian
- Salt Lake City, UT8 kajian
- Boston, MA8 kajian
- Columbus, OH7 kajian
- Pittsburgh, PA7 kajian
Kajian lain di Houston
- Kanser Paru-paru Bukan Sel Kecil145 kajian
- Kanser Payudara126 kajian
- Kanser (semua jenis)121 kajian
- Kanser Metastatik104 kajian
- Kanser Kolorektal102 kajian
- Kanser Ovari89 kajian
- Leukemia Mieloid Akut85 kajian
- Kanser Paru-paru78 kajian
- Kanser Prostat76 kajian
- Kanser Endometrium68 kajian
- Kanser Pankreas61 kajian
- Melanoma59 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.